StockNews.com Upgrades Regulus Therapeutics (NASDAQ:RGLS) to “Sell”

Regulus Therapeutics (NASDAQ:RGLS) was upgraded by stock analysts at StockNews.com to a “sell” rating in a research report issued on Tuesday.

A number of other research firms have also recently commented on RGLS. Canaccord Genuity Group lifted their target price on Regulus Therapeutics from $11.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, June 25th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Regulus Therapeutics in a report on Friday, August 9th. Finally, Oppenheimer reissued an “outperform” rating and set a $7.00 price target on shares of Regulus Therapeutics in a report on Wednesday, August 14th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $10.80.

Regulus Therapeutics Stock Performance

RGLS opened at $1.58 on Tuesday. The business’s 50-day simple moving average is $1.65 and its 200-day simple moving average is $2.04. Regulus Therapeutics has a one year low of $1.08 and a one year high of $3.79. The stock has a market capitalization of $103.44 million, a P/E ratio of -1.08 and a beta of 1.63.

Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.17) EPS for the quarter, hitting analysts’ consensus estimates of ($0.17). On average, equities research analysts forecast that Regulus Therapeutics will post -0.8 EPS for the current fiscal year.

Hedge Funds Weigh In On Regulus Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. NEA Management Company LLC purchased a new stake in Regulus Therapeutics in the 1st quarter valued at approximately $18,627,000. RA Capital Management L.P. purchased a new stake in Regulus Therapeutics in the 1st quarter valued at approximately $18,000,000. CVI Holdings LLC purchased a new stake in Regulus Therapeutics in the 1st quarter valued at approximately $4,050,000. Vanguard Group Inc. boosted its holdings in Regulus Therapeutics by 158.4% in the 1st quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock valued at $2,132,000 after purchasing an additional 453,784 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in Regulus Therapeutics in the 2nd quarter valued at approximately $352,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.